Biote Corp. Class A Common Stock (BTMD) — Analysis Summary
Biote Corp. Class A Common Stock (BTMD) has a market cap of $32.69M with year-over-year revenue growth of -2.5%. Net margin stands at 14.1%. The stock trades at a P/E ratio of 5.6.
Key Takeaways
- Revenue changed -2.5% year-over-year
- Net margin of 14.1%
- P/E ratio of 5.6
Compared to other companies in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS sector, BTMD posted revenue growth of -2.5% and trades at a P/E of 5.6.
Biote Corp. Class A Common Stock (BTMD)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 6.5x — highly leveraged, potential refinancing risk
Shareholder equity is negative, which can signal balance-sheet stress.
Net income fell 78.3% vs the prior period.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Sector
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Employees
223
Headquarters
IRVING, TX
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.